The company’s major shareholder Allied Healthcare Group (AHZ) is working with Coridon founder Ian Frazer to assist in the commercialisation of his work.
Coridon’s technology has been developed to stimulate not only a strong antibody response but also a cellular immune response and is particularly suited to the development of therapeutic vaccines.
The company is also working with the University of Washington on the company’s Herpes Simplex Virus 2 (HSV-2) vaccine.
Coridon plans to start Phase I human trials of the vaccine in 2012.
CEO Neil Finlayson said this technology is being applied to the development of DNA vaccines for a range of infectious diseases and cancer.
"We are very fortunate to be able to work with global leaders on this project and will look at expanding our collaboration as appropriate," Finlayson said.